Christopher Hourigan | EHA 2019 | KESÄKUU 17, 2019
Patients with acute myeloid leukemia (AML) are at risk of relapse after allogeneic hematopoietic cell transplantation (alloHCT). AML measurable residual disease (MRD) status prior to alloHCT has been shown to be prognostic. It is currently unknown if modulating the intensity of the alloHCT conditioning regimen in AML patients testing positive for MRD can prevent relapse and improve survival rates.
Click and hear Christopher Hourigan give the answer.